A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer

被引:18
作者
Guppy, AE
Nelstrop, AE
Foster, T
Agarwal, R
Seckl, MJ
Rustin, GJS
机构
[1] Mt Vernon Ctr Canc Treatment, Dept Med Oncol, Northwood HA6 2RN, Middx, England
[2] Charing Cross Hosp, London W6 8RF, England
关键词
ovarian cancer; sequential chemotherapy;
D O I
10.1038/sj.bjc.6601618
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the sequential use of carboplatin, paclitaxel and topotecan in patients with advanced, previously untreated ovarian cancer. In total, 43 patients with advanced ovarian cancer and >1 cm residual disease were treated with sequential carboplatin (area-under-the-curve (AUC) 5 days 1 and 22), paclitaxel (175 mg m(-2) days 43 and 64) and topotecan (1.5 mg m(-2) daily for 5 days from days 85, 106, 127 and 148). Median age of patients was 6 1 years. Median follow-up was 22.2 months (range 0.76-50.6 months). In all, 34 (79%) patients received all eight cycles of treatment and nine (21%) withdrew. Of the 29 evaluable patients, 19 (66%) responded according to WHO and 30 of 36 (83%) patients according to CA125. The best overall response (CA 125 and/or WHO) was 77% (33 of 43 patients). The response rates to sequential drugs based on >50% fall in CA 125 were as follows: carboplatin, 77% (30 of 39 patients); paclitaxel, 65% (15 of 23 patients); topotecan, 38% (five of 13 patients). Two patients responded to paclitaxel and one to topotecan after failure to respond to preceding chemotherapy. Median survival and time to progression was 22.24 and 10.61 months, respectively. This study demonstrates that sequential chemotherapy with just two initial courses of carboplatin is a reasonable way to introduce new agents into first-line therapy for poor prognostic ovarian cancer patients.
引用
收藏
页码:810 / 814
页数:5
相关论文
共 34 条
  • [1] AVERETTE HE, 1990, CANCER-AM CANCER SOC, V65, P703, DOI 10.1002/1097-0142(19900201)65:3+<703::AID-CNCR2820651314>3.0.CO
  • [2] 2-4
  • [3] Topotecan for the treatment of advanced epithelial ovarian cancer:: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
    Bookman, MA
    Malmström, H
    Bolis, G
    Gordon, A
    Lissoni, A
    Krebs, JB
    Fields, SZ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3345 - 3352
  • [4] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
  • [5] Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
    Creemers, GJ
    Bolis, G
    Gore, M
    Scarfone, G
    Lacave, AJ
    Guastalla, JP
    Despax, R
    Favalli, G
    Kreinberg, R
    VanBelle, S
    Hudson, I
    Verweij, J
    Huinink, WWT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3056 - 3061
  • [6] Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
    Gore, M
    Mainwaring, P
    A'Hern, R
    MacFarlane, V
    Slevin, M
    Harper, P
    Osborne, R
    Mansi, J
    Blake, P
    Wiltshaw, E
    Shepherd, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) : 2426 - 2434
  • [7] A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
    Gore, M
    Oza, A
    Rustin, G
    Malfetano, J
    Calvert, H
    Clarke-Pearson, D
    Carmichael, J
    Ross, G
    Beckman, RA
    Fields, SZ
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) : 57 - 63
  • [8] Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    Huinink, WTB
    Gore, M
    Carmichael, J
    Gordon, A
    Malfetano, J
    Hudson, I
    Broom, C
    Scarabelli, C
    Davidson, N
    Spanczynski, M
    Bolis, G
    Malmstrom, H
    Coleman, R
    Fields, SC
    Heron, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2183 - 2193
  • [9] Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study
    Jakobsen, A
    Bertelsen, K
    Andersen, JE
    Havsteen, H
    Jakobsen, P
    Moeller, KA
    Nielsen, K
    Sandberg, E
    Stroeyer, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 193 - 198
  • [10] Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells
    Kamazawa, S
    Kigawa, J
    Minagawa, Y
    Itamochi, H
    Shimada, M
    Takahashi, M
    Sato, S
    Akeshima, R
    Terakawa, N
    [J]. ONCOLOGY, 2000, 59 (04) : 329 - 335